FGFR3 and lung adenocarcinoma: Clinically, lung adenocarcinoma patients with FGFR3 mutation positive tumors expressing higher activated MAPK levels (supplementary Figure S7, available at Annals of Oncology online) show a better trend in OS with 17 months (n= 8; 95% CI: 6.4–27.5; HR: 0.6) compared with 14 months (n= 197; 95% CI: 8.7–13.2) in patients with wild-type FGFR3 (Figure 2E).